Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- Investigate the possible role of the CYP2C19 genotype in Adenosine diphosphate
(ADP)-induced platelet aggregation after administration of a standard dose regimen of
clopidogrel (300 mg loading dose followed by 75 mg/day for 4 days) in healthy male and
female subjects
Secondary Objectives:
- Assess the pharmacodynamic activity of a higher dose regimen of clopidogrel (600 mg
loading dose followed by 150 mg/day for 4 days)
- Compare the pharmacokinetic profiles of clopidogrel active metabolite between the
selected groups of genotyped subjects and the 2 dose regimen